title: Unexpected Success of Watch and Wait Strategy in a Ponatinib-Intolerant Patient With Chronic Myeloid Leukemia.
authors.affiliation: Ludwig-Maximilians-Universität München, Munich, Germany; and Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
authors.forename: Nils W
authors.initials: NW
authors.lastname: Engel
authors.affiliation: Ludwig-Maximilians-Universität München, Munich, Germany; and Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
authors.forename: André
authors.initials: A
authors.lastname: Constantin
authors.affiliation: Ludwig-Maximilians-Universität München, Munich, Germany; and Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
authors.forename: Sabrina
authors.initials: S
authors.lastname: Fowlkes
authors.affiliation: Ludwig-Maximilians-Universität München, Munich, Germany; and Jewish General Hospital, McGill University, Montreal, Quebec, Canada sarit.assouline@mcgill.ca.
authors.forename: Sarit
authors.initials: S
authors.lastname: Assouline
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors / Q000235:genetics; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D008297:Male; D058990:Molecular Targeted Therapy; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011724:Pyridazines / Q000009:adverse effects*; D012074:Remission Induction; D013997:Time Factors; D016896:Treatment Outcome; D057832:Watchful Waiting
chemical_list: D000970:Antineoplastic Agents; C581634:BCR-ABL1 fusion protein, human; D007093:Imidazoles; D047428:Protein Kinase Inhibitors; D011724:Pyridazines; C545373:ponatinib; D016044:Fusion Proteins, bcr-abl